JP Patent

JP2020510619A — ミカファンギン組成物

Assigned to Baxter International Inc · Expires 2020-04-09 · 6y expired

What this patent protects

非経口投与に適し、貯蔵安定性が増強された水性医薬組成物は、約０．１ｍｇ／ｍＬ〜約４０ｍｇ／ｍＬのミカファンギンと、（ｉｉ）約０．１ｍＭ〜４００ｍＭの緩衝剤と、（ｉｉｉ）約０ｍｇ／ｍＬ〜約５００ｍｇ／ｍＬの等張化剤と、を含み、本組成物のｐＨは約３．０〜７．０、例えば約３．５〜７．０である。

USPTO Abstract

非経口投与に適し、貯蔵安定性が増強された水性医薬組成物は、約０．１ｍｇ／ｍＬ〜約４０ｍｇ／ｍＬのミカファンギンと、（ｉｉ）約０．１ｍＭ〜４００ｍＭの緩衝剤と、（ｉｉｉ）約０ｍｇ／ｍＬ〜約５００ｍｇ／ｍＬの等張化剤と、を含み、本組成物のｐＨは約３．０〜７．０、例えば約３．５〜７．０である。

Drugs covered by this patent

Patent Metadata

Patent number
JP2020510619A
Jurisdiction
JP
Classification
—
Expires
2020-04-09
Drug substance claim
No
Drug product claim
No
Assignee
Baxter International Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.